Details
Stereochemistry | ACHIRAL |
Molecular Formula | C20H28N2O5.ClH |
Molecular Weight | 412.908 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CCC(=O)N(C1=CC=CC=C1)C2(CCN(CCC(=O)OC)CC2)C(=O)OC
InChI
InChIKey=WFBMIPUMYUHANP-UHFFFAOYSA-N
InChI=1S/C20H28N2O5.ClH/c1-4-17(23)22(16-8-6-5-7-9-16)20(19(25)27-3)11-14-21(15-12-20)13-10-18(24)26-2;/h5-9H,4,10-15H2,1-3H3;1H
Remifentanil (marketed by Abbott as Ultiva) is a potent ultra short-acting synthetic opioid analgesic drug. It is given to patients during surgery to relieve pain and as an adjunct to an anaesthetic. ULTIVA is a µ-opioid agonist with rapid onset and peak effect, and short duration of action. The
µ-opioid activity of ULTIVA is antagonized by opioid antagonists such as naloxone. ULTIVA is indicated for IV administration:
1. As an analgesic agent for use during the induction and maintenance of general anesthesia for inpatient and outpatient procedures.
2. For continuation as an analgesic into the immediate postoperative period in adult patients under the direct supervision of an anesthesia practitioner in a postoperative anesthesia care unit or intensive care setting.
3. As an analgesic component of monitored anesthesia care in adult patients.
CNS Activity
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL233 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | ULTIVA Approved UseULTIVA is indicated for IV administration: 1.As an analgesic agent for use during the induction and maintenance of general anesthesia for inpatient and outpatient procedures. 2.For continuation as an analgesic into the immediate postoperative period in adult patients under the direct supervision of an anesthesia practitioner in a postoperative anesthesia care unit or intensive care setting. 3.As an analgesic component of monitored anesthesia care in adult patients. Launch Date1996 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
194 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/14766712 |
6 μg/kg/h 1 times / day other, intravenous dose: 6 μg/kg/h route of administration: Intravenous experiment type: OTHER co-administered: |
REMIFENTANIL ACID blood | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
14 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/14766712 |
6 μg/kg/h 1 times / day other, intravenous dose: 6 μg/kg/h route of administration: Intravenous experiment type: OTHER co-administered: |
REMIFENTANIL blood | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
8080 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/14766712 |
6 μg/kg/h 1 times / day other, intravenous dose: 6 μg/kg/h route of administration: Intravenous experiment type: OTHER co-administered: |
REMIFENTANIL ACID blood | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
745 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/14766712 |
6 μg/kg/h 1 times / day other, intravenous dose: 6 μg/kg/h route of administration: Intravenous experiment type: OTHER co-administered: |
REMIFENTANIL blood | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
2.48 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/14766712 |
6 μg/kg/h 1 times / day other, intravenous dose: 6 μg/kg/h route of administration: Intravenous experiment type: OTHER co-administered: |
REMIFENTANIL ACID blood | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
11.4 min EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/14766712 |
6 μg/kg/h 1 times / day other, intravenous dose: 6 μg/kg/h route of administration: Intravenous experiment type: OTHER co-administered: |
REMIFENTANIL blood | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
30% |
0.5 μg/kg/min 1 times / day other, intravenous dose: 0.5 μg/kg/min route of administration: Intravenous experiment type: OTHER co-administered: |
REMIFENTANIL plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
PubMed
Title | Date | PubMed |
---|---|---|
Target controlled infusion of remifentanil and propofol for cesarean section in a patient with multivalvular disease and severe pulmonary hypertension. | 2001 |
|
Use of remifentanil in combination with desflurane or propofol for ambulatory oral surgery. | 2001 |
|
[Total intravenous anesthesia using remifentanil and propofol with midazolam co-induction in laparoscopic surgery of the gallbladder]. | 2001 |
|
Effects of fentanyl, alfentanil, remifentanil and sufentanil on loss of consciousness and bispectral index during propofol induction of anaesthesia. | 2001 Apr |
|
Ultra-fast-track anesthetic technique facilitates operating room extubation in patients undergoing off-pump coronary revascularization surgery. | 2001 Apr |
|
Remifentanil. | 2001 Aug |
|
[Mastocytosis: general anesthesia with remifentanil and sevoflurane]. | 2001 Aug |
|
Target-controlled infusion or manually controlled infusion of propofol in high-risk patients with severely reduced left ventricular function. | 2001 Aug |
|
The use of remifentanil to facilitate the insertion of the laryngeal mask airway. | 2001 Aug |
|
Effects of combined methohexitone-remifentanil anaesthesia in electroconvulsive therapy. | 2001 Aug |
|
Influence of hypotensive and normotensive anesthesia on platelet aggregability and hemostatic markers in orthognathic surgery. | 2001 Aug 1 |
|
Comparison of effects of remifentanil and alfentanil on cardiovascular response to tracheal intubation in hypertensive patients. | 2001 Jan |
|
Recovery and neurological examination after remifentanil-desflurane or fentanyl-desflurane anaesthesia for carotid artery surgery. | 2001 Jan |
|
Use of remifentanil in a patient with peripartum cardiomyopathy requiring Caesarean section. | 2001 Jan |
|
Opioid chronopharmacology. | 2001 Jul |
|
Anaesthetic management of a child with a positive family history of malignant hyperthermia for posterior fossa surgery in the sitting position. | 2001 Jul |
|
Esmolol is not an alternative to remifentanil for fast-track outpatient gynecologic laparoscopic surgery. | 2001 Jul |
|
Monitored anesthesia care using remifentanil and propofol for awake craniotomy. | 2001 Jul |
|
Postoperative reading speed does not indicate implicit memory in elderly cardiac patients after propofol and remifentanyl anaesthesia. | 2001 Jul |
|
Sevoflurane with remifentanil allows rapid tracheal intubation without neuromuscular blocking agents. | 2001 Jul-Aug |
|
Recovery after remifentanil and sufentanil for analgesia and sedation of mechanically ventilated patients after trauma or major surgery. | 2001 Jun |
|
Bispectral index monitoring in sevoflurane and remifentanil anesthesia. Analysis of drugs management and immediate recovery. | 2001 Jun |
|
Safety and efficacy of remifentanil infusion in craniosynostosis repair in infants. | 2001 Jun |
|
Effect of tracheal intubation or laryngeal mask airway insertion on intraocular pressure using balanced anesthesia with sevoflurane and remifentanil. | 2001 Jun |
|
[Remifentanil for palliative abdominal surgery in a patient with myasthenia gravis]. | 2001 Jun-Jul |
|
Recovery from propofol anaesthesia supplemented with remifentanil. | 2001 Mar |
|
[Esterase-metabolized remifentanil hydrochloride opioid (Ultiva-TM), a new step towards the solution of the problem of regulation of analgetic components of general anesthesia]. | 2001 Mar-Apr |
|
Clonidine decreases propofol requirements during anaesthesia: effect on bispectral index. | 2001 May |
|
[Droperidol and dimenhydrinate alone or in combination for prevention of postoperative nausea and vomiting]. | 2001 May |
|
[General anesthesia with remifentanil in two cases of emergency cesarean section]. | 2001 May |
|
Haemodynamic changes and vasopressin release are not consistently associated with carbon dioxide pneumoperitoneum in humans. | 2001 May |
|
Magnesium as part of balanced general anaesthesia with propofol, remifentanil and mivacurium: a double-blind, randomized prospective study in 50 patients. | 2001 Nov |
|
The bispectral index during an anaphylactic circulatory arrest. | 2001 Oct |
|
Effect of age on recovery from remifentanil anaesthesia. | 2001 Oct |
|
Goal oriented general anesthesia for Cesarean section in a parturient with a large intracranial epidermoid cyst. | 2001 Oct |
|
Threshold-level repetitive transcranial electrical stimulation for intraoperative monitoring of central motor conduction. | 2001 Oct |
|
A comparison of fentanyl, sufentanil, and remifentanil for fast-track cardiac anesthesia. | 2001 Oct |
|
A comparison of propofol and remifentanil for sedation and limitation of movement during periretrobulbar block. | 2001 Sep |
|
Hemodynamics and emergence profile of remifentanil versus fentanyl prospectively compared in a large population of surgical patients. | 2001 Sep |
|
Does functional ability in the postoperative period differ between remifentanil- and fentanyl-based anesthesia? | 2001 Sep |
|
Spontaneous movements, local reactions and pain on injection of rocuronium. A comparison between female and male patients. | 2001 Sep |
|
Effects of remifentanil/propofol in comparison with isoflurane on dynamic cerebrovascular autoregulation in humans. | 2001 Sep |
|
Remifentanil and fentanyl during anaesthesia for major abdominal and gynaecological surgery. An open, comparative study of safety and efficacy. | 2001 Sep |
|
Potential hazard with syringe infusion pump. | 2001 Sep |
|
Facilitation of laryngeal mask airway insertion: effects of remifentanil administered before induction with target-controlled propofol infusion. | 2001 Sep |
|
The in vitro effects of remifentanil, sufentanil, fentanyl, and alfentanil on isolated human right atria. | 2001 Sep |
|
Quantitative EEG changes associated with loss and return of consciousness in healthy adult volunteers anaesthetized with propofol or sevoflurane. | 2001 Sep |
|
Patient-controlled analgesia for labour using remifentanil: a feasibility study. | 2001 Sep |
|
Effects of the opioid remifentanil on olfactory function in healthy volunteers. | 2001 Sep 28 |
|
Effects of cerebrospinal fluid loss and epidural blood patch on cerebral blood flow in swine. | 2001 Sep-Oct |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.drugs.com/dosage/remifentanil.html
Usual Adult Dose for Anesthesia
Induction of Anesthesia: Continuous IV infusion: 0.5 to 1 mcg/kg/min. If endotracheal intubation is to occur in less than 8 minutes, an initial dose of 1 mcg/kg may be administered over 30 to 60 seconds.
Maintenance of Anesthesia: With Nitrous Oxide, 0.4 mg/kg/min by continuous IV infusion.
Infusion dose range: 0.1 to 2 mcg/kg/min.
Supplemental IV bolus: 1 mcg/kg every 2 to 5 minutes.
Route of Administration:
Intravenous
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/16507200
Remifentanil (10(-8) - 10(-4) mol/ L) caused a concentration-dependent vasorelaxation in the human being artery rings.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C67413
Created by
admin on Fri Dec 15 15:30:12 GMT 2023 , Edited by admin on Fri Dec 15 15:30:12 GMT 2023
|
||
|
NCI_THESAURUS |
C1506
Created by
admin on Fri Dec 15 15:30:12 GMT 2023 , Edited by admin on Fri Dec 15 15:30:12 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
5V444H5WIC
Created by
admin on Fri Dec 15 15:30:12 GMT 2023 , Edited by admin on Fri Dec 15 15:30:12 GMT 2023
|
PRIMARY | |||
|
CHEMBL1005
Created by
admin on Fri Dec 15 15:30:12 GMT 2023 , Edited by admin on Fri Dec 15 15:30:12 GMT 2023
|
PRIMARY | |||
|
m9521
Created by
admin on Fri Dec 15 15:30:12 GMT 2023 , Edited by admin on Fri Dec 15 15:30:12 GMT 2023
|
PRIMARY | Merck Index | ||
|
5V444H5WIC
Created by
admin on Fri Dec 15 15:30:12 GMT 2023 , Edited by admin on Fri Dec 15 15:30:12 GMT 2023
|
PRIMARY | |||
|
SUB04215MIG
Created by
admin on Fri Dec 15 15:30:12 GMT 2023 , Edited by admin on Fri Dec 15 15:30:12 GMT 2023
|
PRIMARY | |||
|
236540
Created by
admin on Fri Dec 15 15:30:12 GMT 2023 , Edited by admin on Fri Dec 15 15:30:12 GMT 2023
|
PRIMARY | RxNorm | ||
|
DTXSID50157614
Created by
admin on Fri Dec 15 15:30:12 GMT 2023 , Edited by admin on Fri Dec 15 15:30:12 GMT 2023
|
PRIMARY | |||
|
C47702
Created by
admin on Fri Dec 15 15:30:12 GMT 2023 , Edited by admin on Fri Dec 15 15:30:12 GMT 2023
|
PRIMARY | |||
|
60814
Created by
admin on Fri Dec 15 15:30:12 GMT 2023 , Edited by admin on Fri Dec 15 15:30:12 GMT 2023
|
PRIMARY | |||
|
32091
Created by
admin on Fri Dec 15 15:30:12 GMT 2023 , Edited by admin on Fri Dec 15 15:30:12 GMT 2023
|
PRIMARY | |||
|
100000090469
Created by
admin on Fri Dec 15 15:30:12 GMT 2023 , Edited by admin on Fri Dec 15 15:30:12 GMT 2023
|
PRIMARY | |||
|
132539-07-2
Created by
admin on Fri Dec 15 15:30:12 GMT 2023 , Edited by admin on Fri Dec 15 15:30:12 GMT 2023
|
PRIMARY | |||
|
DBSALT001450
Created by
admin on Fri Dec 15 15:30:12 GMT 2023 , Edited by admin on Fri Dec 15 15:30:12 GMT 2023
|
PRIMARY | |||
|
DD-66
Created by
admin on Fri Dec 15 15:30:12 GMT 2023 , Edited by admin on Fri Dec 15 15:30:12 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD